Kohima News Paper

Psoriasis Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight

 Breaking News
  • No posts were found

Psoriasis Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight

February 26
02:05 2021
Psoriasis Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight

DelveInsight has launched a new report on Psoriasis Pipeline

 

Psoriasis is a chronic, immune mediated inflammatory skin disease characterized by the presence of papules and plaques occurring most commonly on the elbows, knees, scalp, and lower back, but is not limited to these areas.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

 

Psoriasis Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trendsand comparative analysis of Psoriasis Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.

 

Psoriasis Pipeline

The available therapeutics treatment options in Psoriasis Landscape aim to modulate gene transcription, inhibit cell proliferation and promote keratinocyte differentiation.

 

Psoriasis Treatment

Although there is no cure for psoriasis, there are multiple effective treatment options and topical therapy is the standard of care for treatment. Mild to moderate psoriasis can be treated topically with a combination of glucocorticoids, vitamin D analogues, and phototherapy. Systemic treatment is required in moderate to severe cases. Despite its considerable effect on quality of life, psoriasis is underdiagnosed and undertreated. Better understanding of the disease and increase in available treatment options will aid in optimal management and improve patient outcomes in coming years.

 

Marketed drugs included in the report

  • Humira: Abbvie
  • Stelara: Jannsen

 

Emerging drug included in the report

  • Tapinarof (DVMT-505): Dermavant Sciences

 

Psoriasis Report Scope

  • The Psoriasis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Psoriasis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Psoriasis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Psoriasis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Psoriasis.E

 

Request for free sample copy- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

 

Table of content

1. Report Introduction

2. Psoriasis 

3. Psoriasis Current Treatment Patterns

4. Psoriasis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Psoriasis Late Stage Products (Phase-III)

7. Psoriasis mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Psoriasis Discontinued Products

13. Psoriasis Product Profiles

14. Psoriasis Key Companies

15. Psoriasis Key Products

16. Dormant and Discontinued Products

17. Psoriasis Unmet Needs

18. Psoriasis Future Perspectives

19. Psoriasis Analyst Review  

20. Appendix

21. Report Methodology

 

Related Reports

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/